Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.

Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C, Smirnow AM, Thornton CA, Moxley RT 3rd.

Arch Neurol. 2011 Jan;68(1):37-44. doi: 10.1001/archneurol.2010.227. Epub 2010 Sep 13.

3.

Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.

Camacho-Hübner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, Minuto F, Frystyk J, Rogol A, Allan G, Sommer A, Savage MO.

J Clin Endocrinol Metab. 2006 Apr;91(4):1246-53. Epub 2006 Jan 10.

PMID:
16403822
5.

Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.

Guha N, Erotokritou-Mulligan I, Bartlett C, Nevitt SP, Francis M, Bassett EE, Cowan DA, Sönksen PH, Holt RI.

J Clin Endocrinol Metab. 2014 Jun;99(6):2259-68. doi: 10.1210/jc.2013-3897. Epub 2014 Feb 25.

PMID:
24606087
6.

Safety aspects of longitudinal administration of IGF-I/IGFBP-3 complex in neonatal mice.

Hellgren G, Han W, Wang X, Löfqvist C, Hagberg H, Mallard C, Hellström A.

Growth Horm IGF Res. 2011 Aug;21(4):205-11. doi: 10.1016/j.ghir.2011.05.006. Epub 2011 Jun 21.

PMID:
21696987
7.

Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy--a clinical research center study.

Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, Manzione D, Bier DM, Matthews DE, Slonim AE.

J Clin Endocrinol Metab. 1995 Dec;80(12):3715-23.

PMID:
8530624
8.

Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.

Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G.

Growth Horm IGF Res. 2005 Aug;15(4):265-74.

PMID:
16005252
9.

The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes.

Guha N, Nevitt SP, Francis M, Woodland JA, Böhning D, Sönksen PH, Holt RI.

J Clin Endocrinol Metab. 2015 Aug;100(8):3126-31. doi: 10.1210/jc.2015-1996. Epub 2015 Jun 5.

PMID:
26046967
10.

Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.

Regan FM, Williams RM, McDonald A, Umpleby AM, Acerini CL, O'Rahilly S, Hovorka R, Semple RK, Dunger DB.

J Clin Endocrinol Metab. 2010 May;95(5):2113-22. doi: 10.1210/jc.2009-2088. Epub 2010 Mar 16.

PMID:
20233784
11.

Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.

Guha N, Erotokritou-Mulligan I, Nevitt SP, Francis M, Bartlett C, Cowan DA, Bassett EE, Sönksen PH, Holt RI.

Drug Test Anal. 2013 Nov-Dec;5(11-12):843-9. doi: 10.1002/dta.1562. Epub 2013 Oct 31.

PMID:
24173773
12.

Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.

Carroll PV, Umpleby M, Alexander EL, Egel VA, Callison KV, Sönksen PH, Russell-Jones DL.

Clin Endocrinol (Oxf). 1998 Dec;49(6):739-46.

PMID:
10209561
13.

Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats.

Cox GN, McDermott MJ, Merkel E, Stroh CA, Ko SC, Squires CH, Gleason TM, Russell D.

Endocrinology. 1994 Nov;135(5):1913-20.

PMID:
7525258
14.

Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.

Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB.

Diabetes. 2006 Aug;55(8):2365-70.

15.

Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children.

Ferry RJ Jr, Cohen P, Levitt Katz LE.

Horm Res. 2005;63(5):220-7. Epub 2005 May 9.

16.

Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.

Tonella P, Flück CE, Mullis PE.

Horm Res Paediatr. 2010;73(2):140-7. doi: 10.1159/000277660. Epub 2010 Feb 9.

PMID:
20190552
17.

Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.

Boonen S, Rosen C, Bouillon R, Sommer A, McKay M, Rosen D, Adams S, Broos P, Lenaerts J, Raus J, Vanderschueren D, Geusens P.

J Clin Endocrinol Metab. 2002 Apr;87(4):1593-9.

PMID:
11932288
18.

Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): effects on the glycemic and growth promoting activities of rhIGF-1 in the rat.

Clark RG, Mortensen D, Reifsynder D, Mohler M, Etcheverry T, Mukku V.

Growth Regul. 1993 Mar;3(1):50-2.

PMID:
7683530
19.

rhIGF-I/IGFBP-3 complex, but not free rhIGF-I, supports muscle protein biosynthesis in rats during semistarvation.

Svanberg E, Ohlsson C, Kimball SR, Lundholm K.

Eur J Clin Invest. 2000 May;30(5):438-46.

PMID:
10809904
20.

Provision of rhIGF-I/IGFBP-3 complex attenuated development of cancer cachexia in an experimental tumor model.

Wang W, Iresjö BM, Karlsson L, Svanberg E.

Clin Nutr. 2000 Apr;19(2):127-32.

PMID:
10867731
Items per page

Supplemental Content

Write to the Help Desk